Home
CTKB
CTKB News

Latest Cytek Biosciences Inc. (CTKB) News on October 17, 2025

MT Newswires

2 days ago

Cytek Biosciences Relocates European Headquarters to New Facility in Amsterdam

Cytek® Biosciences Expands European Presence with New Facility in Amsterdam to Better Serve Customers and Drive Growth

GlobeNewswire

2 days ago

Cytek® Biosciences Expands European Presence with New Facility in Amsterdam to Better Serve Customers and Drive Growth

Argus Research

10 days ago

CTKB: What does Argus have to say about CTKB?

Cytek Biosciences Brings Full Spectrum Cell Analysis to Leading Clinical Global Conferences ICCS and ESCCA

GlobeNewswire

a month ago

Cytek Biosciences Brings Full Spectrum Cell Analysis to Leading Clinical Global Conferences ICCS and ESCCA

Argus Research

4 months ago

CTKB: What does Argus have to say about CTKB?

Argus Research

4 months ago

CTKB: Raising target price to $3.00

Cytek Biosciences Leads Our Top 3 Penny Stock Selections

Simply Wall St.

4 months ago

Cytek Biosciences Leads Our Top 3 Penny Stock Selections

Cytek Biosciences, Inc. (CTKB) Elevates Cell Analysis with New Aurora Evo System

Insider Monkey

5 months ago

Cytek Biosciences, Inc. (CTKB) Elevates Cell Analysis with New Aurora Evo System

Cytek® Biosciences Is Setting the New Standard for Full Spectrum Flow Cytometry with the New Cytek Aurora™ Evo Flow Cytometer

GlobeNewswire

5 months ago

Cytek® Biosciences Is Setting the New Standard for Full Spectrum Flow Cytometry with the New Cytek Aurora™ Evo Flow Cytometer

Cytek Biosciences to participate at the Goldman Sachs 46th Annual Global Healthcare Conference

GlobeNewswire

5 months ago

Cytek Biosciences to participate at the Goldman Sachs 46th Annual Global Healthcare Conference

Argus Research

5 months ago

CTKB: Lowering target price to $2.00

Cytek Biosciences First Quarter 2025 Earnings: Misses Expectations

Simply Wall St.

5 months ago

Cytek Biosciences First Quarter 2025 Earnings: Misses Expectations

MT Newswires

5 months ago

TD Cowen Downgrades Cytek Biosciences to Hold From Buy, Adjusts Price Target to $4 From $7

GuruFocus.com

5 months ago

Cytek Biosciences Inc (CTKB) Q1 2025 Earnings Call Highlights: Navigating Growth Amid Market ...

Cytek Biosciences, Inc. (CTKB) Reports Q1 Loss, Lags Revenue Estimates

Zacks

5 months ago

Cytek Biosciences, Inc. (CTKB) Reports Q1 Loss, Lags Revenue Estimates

Cytek Biosciences Reports First Quarter 2025 Financial Results

GlobeNewswire

5 months ago

Cytek Biosciences Reports First Quarter 2025 Financial Results

What To Expect From Cytek Biosciences Inc (CTKB) Q1 2025 Earnings

GuruFocus.com

5 months ago

What To Expect From Cytek Biosciences Inc (CTKB) Q1 2025 Earnings

Cytek® Biosciences Brings Cutting-Edge Cell Analysis Solutions to CYTO and IMMUNOLOGY2025

GlobeNewswire

6 months ago

Cytek® Biosciences Brings Cutting-Edge Cell Analysis Solutions to CYTO and IMMUNOLOGY2025

Cytek Biosciences to Report First Quarter 2025 Financial Results on May 8, 2025

GlobeNewswire

6 months ago

Cytek Biosciences to Report First Quarter 2025 Financial Results on May 8, 2025

Argus Research

6 months ago

CTKB: What does Argus have to say about CTKB?

April 2025's Top Penny Stocks To Watch

Simply Wall St.

6 months ago

April 2025's Top Penny Stocks To Watch

Argus Research

6 months ago

CTKB: What does Argus have to say about CTKB?

Argus Research

6 months ago

CTKB: What does Argus have to say about CTKB?

Argus Research

7 months ago

CTKB: What does Argus have to say about CTKB?

Argus Research

7 months ago

CTKB: What does Argus have to say about CTKB?

Cytek® Biosciences Expands Cell Analysis Offerings with the Affordable, User-Friendly Cytek® Muse® Micro System

GlobeNewswire

7 months ago

Cytek® Biosciences Expands Cell Analysis Offerings with the Affordable, User-Friendly Cytek® Muse® Micro System

Open Lending Leads Our Trio Of Promising Penny Stocks

Simply Wall St.

7 months ago

Open Lending Leads Our Trio Of Promising Penny Stocks

Cytek Biosciences, Inc. (CTKB): Why Are Hedge Funds Bullish On This Cash-Rich Penny Stock?

Insider Monkey

7 months ago

Cytek Biosciences, Inc. (CTKB): Why Are Hedge Funds Bullish On This Cash-Rich Penny Stock?

Argus Research

7 months ago

CTKB: Lowering target price to $3.00

Is There An Opportunity With Cytek Biosciences, Inc.'s (NASDAQ:CTKB) 22% Undervaluation?

Simply Wall St.

8 months ago

Is There An Opportunity With Cytek Biosciences, Inc.'s (NASDAQ:CTKB) 22% Undervaluation?

GuruFocus.com

8 months ago

Cytek Biosciences Inc (CTKB) Q4 2024 Earnings Call Highlights: Strong International Growth and ...

Cytek Biosciences, Inc. (CTKB) Tops Q4 Earnings Estimates

Zacks

8 months ago

Cytek Biosciences, Inc. (CTKB) Tops Q4 Earnings Estimates

Cytek Biosciences Reports Fourth Quarter and Full Year 2024 Financial Results and Provides 2025 Outlook

GlobeNewswire

8 months ago

Cytek Biosciences Reports Fourth Quarter and Full Year 2024 Financial Results and Provides 2025 Outlook

GuruFocus.com

8 months ago

Earnings To Watch: Cytek Biosciences Inc (CTKB) Reports Q4 2024 Result

Argus Research

8 months ago

CTKB: What does Argus have to say about CTKB?

Argus Research

8 months ago

CTKB: What does Argus have to say about CTKB?

Cytek Biosciences to Report Fourth Quarter and Full Year 2024 Financial Results on February 27, 2025

GlobeNewswire

8 months ago

Cytek Biosciences to Report Fourth Quarter and Full Year 2024 Financial Results on February 27, 2025

Cytek Biosciences to Participate in Upcoming Investor Conferences

GlobeNewswire

8 months ago

Cytek Biosciences to Participate in Upcoming Investor Conferences

Argus Research

8 months ago

CTKB: Lowering target price to $4.00

MT Newswires

9 months ago

Goldman Sachs Downgrades Cytek Biosciences to Sell From Buy, Adjusts Price Target to $4.50 From $7

Argus Research

9 months ago

CTKB: What does Argus have to say about CTKB?

Cytek Biosciences, Inc. (NASDAQ:CTKB) is largely controlled by institutional shareholders who own 53% of the company

Simply Wall St.

9 months ago

Cytek Biosciences, Inc. (NASDAQ:CTKB) is largely controlled by institutional shareholders who own 53% of the company

Argus Research

9 months ago

CTKB: Lowering target price to $5.00

Cytek Biosciences Announces Preliminary Full Year 2024 Revenue Results

GlobeNewswire

9 months ago

Cytek Biosciences Announces Preliminary Full Year 2024 Revenue Results

Argus Research

9 months ago

CTKB: Raising target price to $7.00

Cytek Biosciences to present at the 43rd Annual J.P. Morgan Healthcare Conference

GlobeNewswire

9 months ago

Cytek Biosciences to present at the 43rd Annual J.P. Morgan Healthcare Conference

MT Newswires

10 months ago

Cytek Biosciences Launches $50 Million Share Buyback

Cytek Biosciences Announces $50 Million Stock Repurchase Program for 2025

GlobeNewswire

10 months ago

Cytek Biosciences Announces $50 Million Stock Repurchase Program for 2025

Argus Research

10 months ago

CTKB: What does Argus have to say about CTKB?

Argus Research

10 months ago

CTKB: What does Argus have to say about CTKB?

Argus Research

10 months ago

CTKB: What does Argus have to say about CTKB?

Argus Research

10 months ago

CTKB: What does Argus have to say about CTKB?

Argus Research

a year ago

CTKB: What does Argus have to say about CTKB?

Cytek Biosciences to participate in the Piper Sandler 36th Annual Healthcare Conference

GlobeNewswire

a year ago

Cytek Biosciences to participate in the Piper Sandler 36th Annual Healthcare Conference

Cytek® Biosciences Named “Overall BioTech Company of the Year” in 2024 BioTech Breakthrough Awards Program

GlobeNewswire

a year ago

Cytek® Biosciences Named “Overall BioTech Company of the Year” in 2024 BioTech Breakthrough Awards Program

Argus Research

a year ago

CTKB: Raising target price to $6.00

Cytek® Biosciences Becomes First Company to Add Ability to Detect Subcellular Particles to Its Cell Sorter

GlobeNewswire

a year ago

Cytek® Biosciences Becomes First Company to Add Ability to Detect Subcellular Particles to Its Cell Sorter

Cytek Biosciences Third Quarter 2024 Earnings: Beats Expectations

Simply Wall St.

a year ago

Cytek Biosciences Third Quarter 2024 Earnings: Beats Expectations

GuruFocus.com

a year ago

Cytek Biosciences Inc (CTKB) Q3 2024 Earnings Call Highlights: Revenue Growth and Positive Net ...

Argus Research

a year ago

CTKB: What does Argus have to say about CTKB?

Cytek Biosciences, Inc. (CTKB) Q3 Earnings and Revenues Beat Estimates

Zacks

a year ago

Cytek Biosciences, Inc. (CTKB) Q3 Earnings and Revenues Beat Estimates

Cytek Biosciences Reports Third Quarter 2024 Financial Results

GlobeNewswire

a year ago

Cytek Biosciences Reports Third Quarter 2024 Financial Results

What To Expect From Cytek Biosciences Inc (CTKB) Q3 2024 Earnings

GuruFocus.com

a year ago

What To Expect From Cytek Biosciences Inc (CTKB) Q3 2024 Earnings

November 2024's Top US Penny Stocks With Growth Potential

Simply Wall St.

a year ago

November 2024's Top US Penny Stocks With Growth Potential

Cytek Biosciences to Participate in Upcoming Investor Conferences

GlobeNewswire

a year ago

Cytek Biosciences to Participate in Upcoming Investor Conferences

Cytek Biosciences to Report Third Quarter 2024 Financial Results on November 5, 2024

GlobeNewswire

a year ago

Cytek Biosciences to Report Third Quarter 2024 Financial Results on November 5, 2024

Argus Research

a year ago

CTKB: What does Argus have to say about CTKB?

Cytek® Biosciences Brings Full Spectrum Profiling™ (FSP™) Technology to the Forefront at Major Clinical Conferences in the U.S. and Europe

GlobeNewswire

a year ago

Cytek® Biosciences Brings Full Spectrum Profiling™ (FSP™) Technology to the Forefront at Major Clinical Conferences in the U.S. and Europe

Cytek Biosciences, Inc.'s (NASDAQ:CTKB) Intrinsic Value Is Potentially 99% Above Its Share Price

Simply Wall St.

a year ago

Cytek Biosciences, Inc.'s (NASDAQ:CTKB) Intrinsic Value Is Potentially 99% Above Its Share Price

MT Newswires

a year ago

Cytek Biosciences COO Chris Williams Resigns

Cytek Announces Resignation of Chief Operating Officer Chris Williams

GlobeNewswire

a year ago

Cytek Announces Resignation of Chief Operating Officer Chris Williams

Argus Research

a year ago

CTKB: What does Argus have to say about CTKB?

Cytek® Biosciences Achieves ISO 13485 Certification at San Diego Reagent Manufacturing Facility

GlobeNewswire

a year ago

Cytek® Biosciences Achieves ISO 13485 Certification at San Diego Reagent Manufacturing Facility

Argus Research

a year ago

CTKB: What does Argus have to say about CTKB?

Cytek Biosciences to Participate in Upcoming Investor Conferences

GlobeNewswire

a year ago

Cytek Biosciences to Participate in Upcoming Investor Conferences

Cytek Biosciences Second Quarter 2024 Earnings: Misses Expectations

Simply Wall St.

a year ago

Cytek Biosciences Second Quarter 2024 Earnings: Misses Expectations

Cytek Biosciences, Inc. (CTKB) Reports Q2 Loss, Lags Revenue Estimates

Zacks

a year ago

Cytek Biosciences, Inc. (CTKB) Reports Q2 Loss, Lags Revenue Estimates

Cytek Biosciences Reports Second Quarter 2024 Financial Results

GlobeNewswire

a year ago

Cytek Biosciences Reports Second Quarter 2024 Financial Results

Cytek® Biosciences Automates Panel Design with New Intelligent Algorithm

GlobeNewswire

a year ago

Cytek® Biosciences Automates Panel Design with New Intelligent Algorithm

Cytek Biosciences to Report Second Quarter 2024 Financial Results on August 6, 2024

GlobeNewswire

a year ago

Cytek Biosciences to Report Second Quarter 2024 Financial Results on August 6, 2024

Argus Research

a year ago

CTKB: What does Argus have to say about CTKB?

Cytek Biosciences, Inc. (NASDAQ:CTKB) is a favorite amongst institutional investors who own 51%

Simply Wall St.

a year ago

Cytek Biosciences, Inc. (NASDAQ:CTKB) is a favorite amongst institutional investors who own 51%

Argus Research

a year ago

CTKB: What does Argus have to say about CTKB?

Argus Research

a year ago

CTKB: Raising target price to $5.00

Cytek Biosciences (CTKB) Moves 5.1% Higher: Will This Strength Last?

Zacks

a year ago

Cytek Biosciences (CTKB) Moves 5.1% Higher: Will This Strength Last?

5 Reasons a Biden Second Term Could Be a Financial Disaster for Boomers

GOBankingRates

a year ago

5 Reasons a Biden Second Term Could Be a Financial Disaster for Boomers

US solar producers could finally have a fighting chance as tariffs kick in on cheaper imports from Asia

Business Insider

a year ago

US solar producers could finally have a fighting chance as tariffs kick in on cheaper imports from Asia

The Best Woody Perfume For Women

Insider Monkey

a year ago

The Best Woody Perfume For Women

Microsoft unveils all-digital Xbox consoles, 'Doom' title at Games Showcase

Reuters

a year ago

Microsoft unveils all-digital Xbox consoles, 'Doom' title at Games Showcase

Insider Monkey

a year ago

Best Date Night Fragrance in 2024

France's Macron calls snap legislative elections after EU poll blow

AFP

a year ago

France's Macron calls snap legislative elections after EU poll blow

Dow Jones Futures Due; Apple AI Push, Fed Rate Outlook Lead 8 Big Market Events

Investor's Business Daily

a year ago

Dow Jones Futures Due; Apple AI Push, Fed Rate Outlook Lead 8 Big Market Events

European Union Vote Delivers Shift to Right, in Blow to French and German Governments

The Wall Street Journal

a year ago

European Union Vote Delivers Shift to Right, in Blow to French and German Governments

MT Newswires

a year ago

Cytek Biosciences Board Approves $50 Million Share Buyback Plan

Cytek Biosciences Announces $50 Million Stock Repurchase Program

GlobeNewswire

a year ago

Cytek Biosciences Announces $50 Million Stock Repurchase Program

Cytek Biosciences to participate at the Goldman Sachs 45th Annual Global Healthcare Conference

GlobeNewswire

a year ago

Cytek Biosciences to participate at the Goldman Sachs 45th Annual Global Healthcare Conference

MT Newswires

a year ago

Cytek Biosciences Gets Approval for Clinical Use of TBNK Reagents in China

1-Laser and 2-Laser 6-Color TBNK Reagents from Cytek® Biosciences Approved for Clinical Use in China

GlobeNewswire

a year ago

1-Laser and 2-Laser 6-Color TBNK Reagents from Cytek® Biosciences Approved for Clinical Use in China

Cytek® Biosciences Adds Ability to Detect Subcellular Particles to Its Industry-Leading Cell Analysis Systems

GlobeNewswire

a year ago

Cytek® Biosciences Adds Ability to Detect Subcellular Particles to Its Industry-Leading Cell Analysis Systems

MT Newswires

a year ago

Piper Sandler Adjusts Price Target on Cytek Biosciences to $8.50 From $10, Maintains Overweight Rating

Share on Social Networks: